Drug Profile
Letolizumab - Bristol-Myers Squibb
Alternative Names: BMS-986004; BMS2h-572-633-CT-L2Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; H. Lee Moffitt Cancer Center and Research Institute
- Class Anti-inflammatories; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Graft-versus-host disease
- No development reported Idiopathic thrombocytopenic purpura
Most Recent Events
- 28 Nov 2022 Bristol Myers Squibb in collaboration with H. Lee Moffitt Cancer Center and Research Institute completes a phase-I/II trial in Graft-versus-host disease (Prevention) in USA (IV) (NCT03605927)
- 08 Mar 2021 No recent reports of development identified - Phase-I/II for Idiopathic thrombocytopenic purpura in USA, Georgia, Poland, Moldova, United Kingdom, Canada, Australia, Russia (IV)
- 24 Jan 2019 Phase-I/II clinical trials in Graft-versus-host disease (Prevention) in USA (IV) (NCT03605927)